Reprint

Breast Cancer—Therapeutic Challenges, Research Strategies and Novel Diagnostics

Edited by
November 2023
282 pages
  • ISBN978-3-0365-9443-9 (Hardback)
  • ISBN978-3-0365-9442-2 (PDF)

This is a Reprint of the Special Issue Breast Cancer—Therapeutic Challenges, Research Strategies and Novel Diagnostics that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Thanks to the breast cancer research of recent decades, effective methods and strategies have been established, allowing the mortality rates of breast cancer patients to decrease more and more. However, we still face many challenges. The role of certain biomarkers or mutations is still not clear for treatment and surveillance. Novel drugs are often associated with a different spectrum of adverse events than that seen for conventional therapies, accordingly having an impact on patients’ compliance behaviors. In breast cancer surgery, in some cases, the question remains whether to escalate or deescalate. Additionally, with regard to diagnostics, in a digitalized world, home-based tools and therapy monitoring options are of high importance, especially under the tough conditions and supply problems seen during the COVID-19 pandemic.This Special Issue gathers original research articles and reviews demonstrating therapeutic challenges, current research strategies, and novel diagnostics in breast cancer.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
pannexin 1 (PANX1); neutrophils; adenosine; tumor microenvironment (TME); breast cancer; breast cancer; ER heterogeneity; 18F-FES PET/CT; diagnosis; treatment pattern; metastatic breast cancer; heterogeneity; HER2; 18F-fluorodeoxyglucose positron emission tomography/computed tomography; pyrotinib; therapy response; oncotype DX; recurrence score; breast cancer; individualized therapy; advanced breast cancer; breast cancer susceptibility genes 1 and 2; genetic testing; human epidermal growth factor receptor 2—negative; poly(adenosine diphosphate-ribose) polymerase inhibitors; real-world; machine learning; breast cancer; neoadjuvant systemic treatment; lymph node metastasis; phytochemicals; nanocarriers; breast cancer; chemotherapy; drug resistance; risk prediction models; breast cancer screening; risk assessment; risk-based screening; breast cancer; localization technique; non-palpable lesion; intraoperative ultrasound; wire-guided localization; magnetic seed; radioactive seed; radar reflector; radiofrequency identification tag; oncology; telemedicine; telerehabilitation; psychological well-being; cognitive impairment; rehabilitation; cancer side effects; breast cancer; metastasis; treatment; human epidermal growth factor receptor 2; hormone receptor; registries; breast cancer; endocrine treatment; CDK4/6 inhibitor; abemaciclib; dalpiciclib; palbociclib; ribociclib; Contrast-Enhanced Mammography; Digital Breast Tomosynthesis; breast cancer screening; Average Glandular Dose; TNBC; LEMD1; ERK; therapeutic target; BOUNCE; breast cancer; coping self-efficacy; fear of cancer recurrence; latent growth modeling; trajectories; n/a